§ 01 Overview
Overview
Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
§ 02 Mechanism
Mechanism of action
Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- 01Substantial weight loss in Phase III (GLORY-1)
- 02Improvements in hepatic fat and liver enzymes
- 03Glycemic improvements in T2D
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 10 mg
- BAC Water
- 1 ml BAC water
- Dose Range
- 3 – 9 mg weekly
- Starting Dose
- 3 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
FDA Status
Not FDA-approved. Approved in China (2025).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Mazdutide Shows Weight Reductions for Patients With Obesity - Drug Topics
Mazdutide Shows Weight Reductions for Patients With Obesity Drug Topics
9 mg Mazdutide for Effective Weight Loss in Chinese Adults with Obesity - Bioengineer.org
9 mg Mazdutide for Effective Weight Loss in Chinese Adults with Obesity Bioengineer.org
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions - The Manila Times
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions The Manila Times
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? - Ro
Mazdutide vs. Tirzepatide: Which Is Better for Weight Control? Ro
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial - EMJ
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial EMJ
Top China Pharma and Biotech Stocks to Watch, According to Bernstein - Investing.com
Top China Pharma and Biotech Stocks to Watch, According to Bernstein Investing.com
Chinese researchers make significant progress in diabetes treatment - Xinhua
Chinese researchers make significant progress in diabetes treatment Xinhua
Chinese researchers make significant progress in diabetes treatment - The Macau Post Daily
Chinese researchers make significant progress in diabetes treatment The Macau Post Daily
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02GI effects typical of incretin class
Contraindications
None specified.